{"id":295530,"date":"2026-05-05T00:00:00","date_gmt":"2026-05-05T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneon0019-2024-biopharma-breast-cancer-unmet-need-unmet-need-metastatic-hr-positive-her2-negative\/"},"modified":"2026-05-29T23:12:05","modified_gmt":"2026-05-29T23:12:05","slug":"unneon0019-2026-biopharma-breast-cancer-unmet-need-unmet-need-metastatic-hr-positive-her2-negative-breast-cancer-us","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneon0019-2026-biopharma-breast-cancer-unmet-need-unmet-need-metastatic-hr-positive-her2-negative-breast-cancer-us\/","title":{"rendered":"Breast Cancer &#8211; Unmet Need &#8211; Unmet Need &#8211; Metastatic HR-Positive \/ HER2-Negative Breast Cancer (US\/EU)"},"content":{"rendered":"<p>The landscape of advanced <abbr title=\"hormone receptor\">HR<\/abbr>-positive \/ <abbr title=\"human epidermal growth factor receptor-2\">HER2<\/abbr>-negative breast cancer treatment is continually evolving. <abbr title=\"cyclin-dependent kinase 4\">CDK4<\/abbr>\/6 inhibitors (Pfizer\u2019s Ibrance, Novartis\u2019s Kisqali, and Eli Lilly\u2019s Verzenio) combined with endocrine therapy are established first-line treatments. These agents have significantly improved outcomes for patients with hormone-receptor-positive tumors. However, there is an urgent need for effective later-line treatments. Biomarker-driven therapies, including Menarini\u2019s Orserdu (<i>ESR1<\/i>-mutant), Novartis\u2019s Piqray (<i><abbr title=\"phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform\">PIK3CA<\/abbr><\/i>-mutant) and\u00a0AstraZeneca\u2019s Truqap (<i><abbr title=\"phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform\">PIK3CA<\/abbr>\/AKT1\/<\/i><i><abbr title=\"phosphatase and tensin\u00a0homolog\">PTEN<\/abbr><\/i>-mutant) have expanded treatment options for metastatic <abbr title=\"hormone receptor\">HR<\/abbr>-positive \/ <abbr title=\"human epidermal growth factor receptor-2\">HER2<\/abbr>-negative disease. As competition intensifies, novel therapies that address key unmet needs could offer welcome diversification in real-world practice.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul class=\"BulletListStyle1 SCXW92580611 BCX0 round-bullets\">\n<li>What is the level of satisfaction among U.S and European medical oncologists with current treatments for metastatic <abbr title=\"hormone receptor\">HR<\/abbr>-positive \/ <abbr title=\"human epidermal growth factor receptor-2\">HER2<\/abbr>-negative breast cancer?<\/li>\n<li>What key factors influence medical oncologists\u2019 decisions when prescribing treatments for metastatic <abbr title=\"hormone receptor\">HR<\/abbr>-positive \/ <abbr title=\"human epidermal growth factor receptor-2\">HER2<\/abbr>-negative breast cancer? How do key current therapies perform on these key attributes?<\/li>\n<li>What are the untapped opportunities and unmet needs in this patient subpopulation?<\/li>\n<li>What trade-offs are U.S. and European oncologists willing to make regarding cost and clinical features for a new metastatic <abbr title=\"hormone receptor\">HR<\/abbr>-positive \/ <abbr title=\"human epidermal growth factor receptor-2\">HER2<\/abbr>-negative breast cancer drug?<\/li>\n<\/ul>\n<p><strong>Markets covered:<\/strong> United States, United Kingdom, France, Germany<\/p>\n<p><strong>Primary research: <\/strong>Survey of 60 U.S. and 31 European medical oncologists fielded in March 2026<\/p>\n<p><strong>Key drugs:<\/strong> Ibrance, Kisqali, Verzenio \/ Verzenios, Piqray, Orserdu, Truqap, everolimus<\/p>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p><a>Unmet Need offers insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities, enabling you to:<\/a><\/p>\n<ul class=\"round-bullets\">\n<li>Evaluate clinical and nonclinical product attributes that influence treatment decisions through physicians\u2019 weightings and analysis of stated vs. derived importance.<\/li>\n<li>Pinpoint areas of high unmet need by assessing current drug performance against key attributes and treatment drivers.<\/li>\n<li>Analyze market scenarios for different target product profiles using the <abbr title=\"Target Product Profile\">TPP<\/abbr> Simulator.<\/li>\n<\/ul>\n<p><strong>KEY FEATURE<\/strong><\/p>\n<p>Target Product Profile (<abbr title=\"Target Product Profile\">TPP<\/abbr>) simulator tool allows for customizable market simulations based on conjoint analysis. Compare up to seven <abbr title=\"Target Product Profile\">TPP<\/abbr>s across multiple disease-specific attributes and price points to gauge which variables influence prescribing behavior.<\/p>\n","protected":false},"template":"","class_list":["post-295530","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-breast-cancer","biopharma-therapy-areas-solid-tumors","biopharma-product-unmet-need","biopharma-geography-us","biopharma-date-2609"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/295530","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":3,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/295530\/revisions"}],"predecessor-version":[{"id":581120,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/295530\/revisions\/581120"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=295530"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}